SCHEMBL12609668

SCHEMBL12609668

CCN1C(=O)C(=C2SC=CS2)C(=O)N(CC)C1=S

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.50
KMT2A Q03164 8/20 0.50
RXFP1 Q9HBX9 2/20 0.50
TNFRSF1A P19438 4/20 0.45
ALDH1A1 P00352 12/20 0.44
MAPT P10636 12/20 0.44
HPGD P15428 3/20 0.44
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
POLB P06746 2/20 0.44
NPC1 O15118 2/20 0.44
MAPK1 P28482 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.39
GAA P10253 2/20 0.37
ALOX12 P18054 1/20 0.37
ATM Q13315 1/20 0.36
HTT P42858 3/20 0.35
KDM4C Q9H3R0 2/20 0.35
KDM4E B2RXH2 2/20 0.35
THRB P10828 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12609730 0.80 MEN1 (0.49) MEN1KMT2ARXFP1TNFRSF1AALDH1A1
SCHEMBL12609626 0.78 MEN1 (0.44) MEN1KMT2ARXFP1TNFRSF1AALDH1A1
SCHEMBL22174138 0.78 MEN1 (0.48) MEN1KMT2ARXFP1TNFRSF1AALDH1A1
SCHEMBL14020128 0.78 MEN1 (0.46) MEN1KMT2ARXFP1TNFRSF1AALDH1A1
SCHEMBL12609622 0.78 KMT2A (0.50) MEN1KMT2ARXFP1TNFRSF1AALDH1A1
SCHEMBL14414122 0.76 MEN1 (0.46) MEN1KMT2ARXFP1TNFRSF1AALDH1A1
SCHEMBL2631038 0.76 MEN1 (0.42) MEN1KMT2ARXFP1TNFRSF1AALDH1A1
SCHEMBL12609655 0.74 MEN1 (0.43) MEN1KMT2ARXFP1TNFRSF1AALDH1A1
SCHEMBL12609637 0.74 NR1H2 (0.43) MEN1KMT2ARXFP1TNFRSF1AALDH1A1
SCHEMBL13777421 0.74 MEN1 (0.43) MEN1KMT2ARXFP1TNFRSF1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110123929-A1 OXIME COMPOUND, PHOTOSENSITIVE COMPOSITION, COLOR FILTER, PRODUCTION METHOD FOR THE COLOR FILTER, AND LIQUID CRYSTAL DISPLAY ELEMENT FUJIFILM CORPORATION (JP) 2011-05-26 US disclosed
US-20110123929-A1 OXIME COMPOUND, PHOTOSENSITIVE COMPOSITION, COLOR FILTER, PRODUCTION METHOD FOR THE COLOR FILTER, AND LIQUID CRYSTAL DISPLAY ELEMENT FUJIFILM CORPORATION (JP) 2011-05-26 US disclosed
EP-2116527-A1 OXIME COMPOUND, PHOTOSENSITIVE COMPOSITION, COLOR FILTER, METHOD FOR PRODUCTION OF THE COLOR FILTER, AND LIQUID CRYSTAL DISPLAY ELEMENT FUJIFILM Corporation (JP) 2009-11-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110123929-A1 OXIME COMPOUND, PHOTOSENSITIVE COMPOSITION, COLOR FILTER, PRODUCTION METHOD FOR THE COLOR FILTER, AND LIQUID CRYSTAL DISPLAY ELEMENT PPOX, CRY2, HCCS MEN1 4248/4885KMT2A 476/4885RXFP1 656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.